Evaluate treatment persistence in chronic hypertensive patients who have di erent percentages of nancial subsidy in a Program Bene t Management (PBM).
INTRODUCTION

METHODS
General characteristics of health insurance companies in relation to subsidy:
In Company 1 the subsidy varies according to the salary between 15% to 40%, but these medications have 40% of subsidy. The most important factor would be the patient's own decision to participate in the bene t, because this company is not inserted into a program that sends the product to the patient's home or work as in the case of rms 2 and 3, on the contrary, the patient have the inconvenient to go to a partner pharmacy closest to your home or work to use the bene t.
Company 2 have a really interesting case, since the group manager of the company sets the percentage of allowance for of drugs used, which can be brand (70%) or Generic (90%). For products said brand in Brazil have considered Referenced drugs, or who have pioneered the discovery of the referenced and Similar, which are products on the market after the patent expiration of reference products and must follow speci c rules for performing the same role in treatment. To pass both exams: bioavailability and bioequivalence defined by Brazilian National Health Vigilance Agency (ANVISA). 
RESULTS
CONCLUSION
In only one case the company with less subsidy had the higher persistency. But the di erence was small (1.24% between the two companies), yet by some factor not assessed in this study that interfere with the results. The incident occurred with the active Amlodipine between the companies 2 and 3. Only in this case the company 2 obtained a higher percentage of adherence than company 3.
It became clear in this study that the average persistence varies statistically signi cant according to the percentage of subsidy equal and controlled environments, where obviously no impediments to persistence as, for example, di culties of access (remote, di erent eligibility rules di erences in the provision of drug bene t, etc.).
Companies 2 and 3 subsidize chronic treatments as hypertension, at a proportion greater than 2 times the company 1. So too the answer persistency.
This program prevents higher hospital costs. Maximum subsidy of 40% of the s a l e pri ce (PV) of the drug i ncl udi ng ma rket di s count on the ma xi mum pri ce to the cons umer (PMC). The percenta ge of the a l l owa nce i s determi ned by the ori enta tion of the hea l th depa rtment of the compa ny, a nd va ri es a ccordi ng to the s a l a ry ra nge Maximum subsidy of 90% on the s el l i ng pri ce (PV) of the drug i ncl udi ng ma rket di s count on the ma xi mum pri ce to the cons umer (PMC). Thi s percenta ge of s ubs i dy a nd defined onl y for generi c drugs .
For bra nded products or s i mi l a r references the s ubs i dy i s 70% of the s a l e pri ce. But for the pres ent s tudy were a l l i nvol ved generi c medi ca tions .
Maximum grant of 100% of the s a l e pri ce (PV) of the drug i ncl udi ng ma rket di s count on the ma xi mum pri ce to the cons umer (PMC). The percenta ge of the a l l owa nce i s determi ned by the ori enta tion of the hea l th depa rtment of the compa ny. In thi s progra m the el i gi bl e pa tient does not pa y a nythi ng for trea tment. These results can be seen in the tables and gure below: 
